This initiative has been supported by Helsinn through an unrestricted educational grant to Magdalen Medical Publishing Ltd
Watch Guillermo Garcia-Manero, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, highlight the issues around treating acute myeloid leukemia (AML) in the elderly and potential approaches to combat these. While hypomethylating agents are a mainstay therapy in this patient group, it is nevertheless important to treat each elderly patient on a case by case basis. Dr Garcia-Manero presents some of these options, which include chemotherapy, as well as novel compounds that target specific mutations.
Alternative approaches to AML in the over 70s
Novel targets and compounds for AML in the elderly
Efficacy and safety of pracinostat-azacitidine in elderly AML
Principal investigator, Dr Garcia-Manero, outlines the rationale, design and significance of this large Phase III study with the combination of pracinostat and azacitidine in elderly AML patients. Following promising Phase II data with pracinostat, this current Phase III study aims to establish in more detail the efficacy of the histone deacetylase (HDAC) inhibitor when combined with a hypomethylating agent.
Exploring future combinations with immunotherapy in AML
HDAC inhibitor-hypomethylating agent combinations in elderly AML patients
Factors to consider in allogeneic transplant in AML
The age-old discussion: managing AML in the elderly
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, chairs a dynamic discussion with fellow AML specialists, Farhad Ravandi, MD, and Naval Daver, MD, both from the University of Texas MD Anderson Cancer Center, Houston, TX. Together they explore different perspectives on the treatment of AML in older adults and evaluate future treatment options. Aspects discussed by the physicians include whether or not to consider transplant, if and how much chemotherapy can be administered to their older patients before hypomethylating agents are prescribed, inclusion of patients in clinical trials in order to gain access to novel treatments, and how current studies with HDAC inhibitors could benefit their patients in the future.
HDAC inhibitor studies may increase treatment options in AML
Intensive chemotherapy, low-intensity therapy, or transplant for AML?
Current experience with novel agents and combinations in elderly AML
Debate on novel therapies for elderly AML and MRD assessment
Evaluating the treatment benefits of the pracinostat-azacitadine combination in adults with AML. Phase III trial currently recruiting
Recruitment for this Phase III study is currently underway. Adults aged over 18 with newly diagnosed AML are being considered for inclusion in this global, large-scale, multi-centre, double-blind, randomized study comparing the combination of pracinostat with azacitidine or a placebo. To find out more about the Phase III trial, NCT03151408, and enquire about recruitment visit the clinical trials website.